Dun, M. D., Jackson, E. R., Duchatel, R. J., Persson, M. L., Mannan, A., Yadavilli, S., Parackal, S., Game, S., Chong, W. C., Jayasekara, S., Le Grand, M., Kearney, P. S., Douglas, A. M., Findlay, I. J., Staudt, D., Germon, Z. P., Skerrett-Byrne, D. A., Nixon, B., Smith, N. D., Hulleman, E., Day, B., McCowage, G. B., Alvaro, F., Waszak, S. M., Larsen, M. R., Colino-Sanguino, Y., Valdes-Mora, F., Rakotomalala, A., Meignan, S., Pasquier, E., Vitanza, N. A., Nazarian, J., Koschmann, C., Cain, J., & Mueller, S. (n.d.). dIPG-07. Preclinical and case study results underpinning the phase II clinical trial testing the combination of ONC201 and paxalisib for the treatment of patients with diffuse midline glioma (NCT05009992). Neuro-oncology, 24, i18–i19. http://access.bl.uk/ark:/81055/vdc_100156448088.0x000024